NEW YORK – Horizon Discovery said on Tuesday that it has granted two commercial licenses for its CHOSource platform to biotechnology company Sanyou Biopharmaceuticals.
Sanyou will use Horizon's gene-edited Glutamine Synthetase knockout Chinese Hamster Ovary (CHO) K1 cell line for the development of preclinical antibody drug projects and to support the clinical development and commercialization of its customers' human biotherapeutic products. Sanyou will also offer CHOSource through its contract research services, Horizon added.